Cancer Methylation Panel Assay Kits

The silencing of tumor suppressor genes via DNA hypermethylation and the overexpression of transposable elements via global DNA hypomethylation are well-known patterns of cancer cell formation. The discovery of cancer DNA methylation biomarkers is important for the improvement and design of cancer therapies. The 28 genes of the Cancer Panel were selected from prior breast cancer studies. However, the panel is customizable to exclude or include any target regions of your interest. All methylation assays of the Cancer Panel were individually validated using DNA extracted from FFPE samples, but a subset of the panel was also validated using cell-free serum plasma DNA. Analyze the entire panel using targeted Next-Generation Bisulfite Sequencing, or analyze a few select regions using Pyrosequencing.

• Compatible with targeted Next-Gen Bisulfite Sequencing, MS-HRM, and Pyrosequencing
• Ready-to-use assays for specificically amplification of bisulfite converted DNA
• Master mix with convenient PCR set up
• Optimized assay protocol
• Primers good for 300 reactions.
• Access to our knowledgeable and experienced customer service.

Genes validated on FFPE samples: APC, BRCA1, CD44, CDKN1A, CDKN2A, CST6, DAPK1, EN1, ESR1, ESR2, GSTM2, GSTP1, HIST1H3C, HOXB4, LHX2, MAGEA1, PARP1, PDGFRA, PGR, PTGS2, RARB, RASGRF2, RASSF1, RUNX3, SGK1H, SOX17, TFF1, TMEFF2
Gene validated on serum plasma DNA: APC, BRCA1, CDKN2A, CST6, DAPK1, ESR2, GSTP1, HIST1H3C, HOXB4, RARB, RASGRF2, RUNX3, SOX17, TMEFF2

Please contact us at for specific academic pricing.